Creative Medical Technology Holdings Inc Dossier
Qualitative Analysis
Business overview
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. The company's business model centers on developing cell-based therapeutic candidates and creating, protecting, and licensing its expanding intellectual property portfolio. Its core pipeline includes AlloStem (CELZ-201-DDT), an allogeneic human perinatal tissue-derived cell program; ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; and CELZ-201 CREATE-1, an intervention targeting recent-onset Type 1 Diabetes. Additionally, the company markets CaverStem for erectile dysfunction and FemCelz for female sexual dysfunction.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
An AI-enabled regenerative defense program designed to build a comprehensive molecular and cellular database for veterans affected by toxic burn pit exposure, utilizing the company's proprietary iPSC platform.
Expected impact: Establishes a scalable national capability in regenerative biodefense and decodes genomic/proteomic signatures of toxic exposure without incremental balance sheet pressure.
Expanding the CELZ-201 platform into scalable, cell-free regenerative therapies using the biological signaling components of Olastrocel.
Expected impact: Enables off-the-shelf availability, simplified outpatient execution, and significantly reduced production costs compared to cell-based therapies.
Leveraging artificial intelligence and genetic engineering to develop human induced pluripotent stem cell (iPSC) derived pancreatic islet cells for diabetes treatment.
Expected impact: Aims to identify small molecules that enhance insulin secretion and create stealth cell lines with enhanced survival and differentiation capabilities.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High strategic importance as it integrates AI-driven drug discovery and multi-gene editing with Creative Medical's iPSC platform to advance diabetes and biodefense programs.
Terms: Executed under long-standing collaboration agreements with favorable commercial terms, avoiding incremental capital raises.
Medium strategic importance; used as a vehicle for strategic investments, including a contribution of $43,200 in November 2025 to invest in Applife Digital Solutions, Inc.
Terms: Creative Medical contributed $43,200 to the joint venture in late 2025.